Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease

[1]  Henrik Antti,et al.  Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. , 2016, Molecular bioSystems.

[2]  S. Adams,et al.  Acylcarnitines—old actors auditioning for new roles in metabolic physiology , 2015, Nature Reviews Endocrinology.

[3]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[4]  V. Mok,et al.  Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson’s disease , 2015, Scientific Reports.

[5]  L. Forsgren,et al.  NMR metabonomics of cerebrospinal fluid distinguishes between Parkinson’s disease and controls , 2015, Neuroscience Letters.

[6]  A. Nordström,et al.  Low muscle strength in late adolescence and Parkinson disease later in life , 2015, Neurology.

[7]  L. Ermini,et al.  Disruption of sphingolipid metabolism augments ceramide-induced autophagy in preeclampsia , 2015, Autophagy.

[8]  Nobutaka Hattori,et al.  Identification of novel biomarkers for Parkinson's disease by metabolomic technologies , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  K. Ohno,et al.  CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study , 2015, The Lancet Neurology.

[10]  Zongwei Cai,et al.  LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease. , 2015, Journal of proteome research.

[11]  Leah Rider,et al.  Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer , 2014, Molecular Cancer Therapeutics.

[12]  N. Mercuri,et al.  Serotonin Impairment in CSF of PD Patients, without an Apparent Clinical Counterpart , 2014, PloS one.

[13]  Oliver A.H. Jones.  Metabolomics and systems biology in human health and medicine. , 2014 .

[14]  M. Stumvoll,et al.  Serum Levels of Acylcarnitines Are Altered in Prediabetic Conditions , 2013, PloS one.

[15]  Dean P. Jones,et al.  Serum Metabolomics of Slow vs. Rapid Motor Progression Parkinson’s Disease: a Pilot Study , 2013, PloS one.

[16]  C. Adler,et al.  3‐hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis , 2013, Movement disorders : official journal of the Movement Disorder Society.

[17]  Y. Ishihama,et al.  Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry , 2012, Metabolomics.

[18]  J. Jankovic,et al.  Therapies in Parkinson's disease. , 2012, Current opinion in neurology.

[19]  Anna Jaskólska,et al.  Myometry revealed medication-induced decrease in resting skeletal muscle stiffness in Parkinson's disease patients. , 2012, Clinical biomechanics.

[20]  A. Lang,et al.  How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. , 2012, Brain : a journal of neurology.

[21]  R. Rodríguez‐Gutiérrez,et al.  Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study , 2012, Journal of the International Society of Sports Nutrition.

[22]  Masaru Tomita,et al.  Bioinformatics Tools for Mass Spectroscopy-Based Metabolomic Data Processing and Analysis , 2012, Current bioinformatics.

[23]  이은직.  The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. , 2012 .

[24]  C. Newgard,et al.  Daily variation of serum acylcarnitines and amino acids , 2011, Metabolomics.

[25]  N. Hattori,et al.  Molecular pathogenesis of Parkinson's disease: update , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  Masaaki Komatsu,et al.  Autophagy: Renovation of Cells and Tissues , 2011, Cell.

[27]  B. Averbeck,et al.  Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  Masaru Tomita,et al.  Metabolomic anatomy of an animal model revealing homeostatic imbalances in dyslipidaemia. , 2011, Molecular bioSystems.

[29]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[30]  V. De Riva,et al.  Plasma and urinary HPLC-ED determination of the ratio of 8-OHdG/2-dG in Parkinson's disease. , 2011, Clinical laboratory.

[31]  Gwang Lee,et al.  Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[32]  F. Toledo,et al.  Increased Levels of Plasma Acylcarnitines in Obesity and Type 2 Diabetes and Identification of a Marker of Glucolipotoxicity , 2010, Obesity.

[33]  A. Schatzkin,et al.  Physical activities and future risk of Parkinson disease , 2010, Neurology.

[34]  Fritz Schick,et al.  Medium Chain Acylcarnitines Dominate the Metabolite Pattern in Humans under Moderate Intensity Exercise and Support Lipid Oxidation , 2010, PloS one.

[35]  Winkins Santosh,et al.  Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection , 2009, Journal of Biomedical Science.

[36]  William E. Kraus,et al.  Relationships Between Circulating Metabolic Intermediates and Insulin Action in Overweight to Obese, Inactive Men and Women , 2009, Diabetes Care.

[37]  C. Hoppel,et al.  Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. , 2009, The Journal of nutrition.

[38]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[39]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[40]  A. Kupsch,et al.  Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson’s disease , 2008, European Journal of Clinical Pharmacology.

[41]  Masaru Tomita,et al.  Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. , 2008, Molecular bioSystems.

[42]  Michael J Thun,et al.  Recreational physical activity and risk of Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[43]  K. Kashihara.  Weight loss in Parkinson’s disease , 2006, Journal of Neurology.

[44]  Masaaki Komatsu,et al.  Autophagy and Neurodegeneration , 2006, Autophagy.

[45]  H. Chen,et al.  Physical activity and the risk of Parkinson disease , 2005, Neurology.

[46]  Masaru Tomita,et al.  Simultaneous determination of the main metabolites in rice leaves using capillary electrophoresis mass spectrometry and capillary electrophoresis diode array detection. , 2004, The Plant journal : for cell and molecular biology.

[47]  D. Piomelli,et al.  Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor α (PPAR-α)* , 2004, Journal of Biological Chemistry.

[48]  D. Piomelli,et al.  Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). , 2004, The Journal of biological chemistry.

[49]  M. Tomita,et al.  Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. , 2003, Journal of proteome research.

[50]  A. Lang,et al.  Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. , 2002, JAMA.

[51]  D. Chace,et al.  Rapid diagnosis of methylmalonic and propionic acidemias: quantitative tandem mass spectrometric analysis of propionylcarnitine in filter-paper blood specimens obtained from newborns. , 2001, Clinical chemistry.

[52]  M. Hoehn,et al.  Parkinsonism , 1998, Neurology.

[53]  M. Wyss,et al.  Creatine and creatinine metabolism. , 2000, Physiological reviews.

[54]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[55]  R. Dobbs,et al.  Cortisol is higher in parkinsonism and associated with gait deficit , 1998, Acta neurologica Scandinavica.

[56]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[57]  I. Heuser,et al.  Twenty-Four Hour Cortisol Release Profiles in Patients With Alzheimer’s and Parkinson’s Disease Compared to Normal Controls: Ultradian Secretory Pulsatility and Diurnal Variation , 1997, Neurobiology of Aging.

[58]  J. McGarry,et al.  The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. , 1997, European journal of biochemistry.

[59]  Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group. , 1995, Archives of neurology.

[60]  O. Blin,et al.  Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy , 1994, Journal of the Neurological Sciences.

[61]  C. Marín,et al.  Mitochondria1 respiratory chain activity in skeletal muscle from patients with Parkinson's disease , 1993, Neurology.

[62]  E. Tolosa,et al.  Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. , 1993, Neurology.

[63]  C. Marsden,et al.  Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.

[64]  C. Marsden,et al.  Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. , 1992, Annals of neurology.

[65]  H. Yoshino,et al.  Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[66]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[67]  W. Koller,et al.  Muscle strength testing in Parkinson's disease. , 1986, European neurology.

[68]  S. Genuth,et al.  Carnitine metabolism in normal-weight and obese human subjects during fasting. , 1980, The American journal of physiology.

[69]  M. Girard.  [Therapy of Parkinson's disease]. , 1952, Journal de medecine de Lyon.